

Amendments to the claims:

Claims 1-64 (canceled)

65. (original) A method of inhibiting a T-cell mediated immune response in a mammal, comprising exposing mammalian cells to DcR3 polypeptide or a chimeric molecule comprising DcR3 polypeptide.

66. (canceled)

67. (new) A method of treating or preventing an inflammatory disease or disorder comprising administering to an animal a therapeutically effective amount of a polypeptide selected from the group consisting of: (a) a polypeptide comprising amino acid residues 1 to 300 of SEQ ID NO:1; (b) a polypeptide comprising amino acid residues 24 to 300 of SEQ ID NO:1; (c) a polypeptide comprising amino acid residues 24 to 215 of SEQ ID NO:1; (d) a polypeptide comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254; and (e) a polypeptide comprising the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254.

68. (new) The method of claim 67 wherein the animal is human.

69. (new) The method of claim 67 wherein the polypeptide is fused to a heterologous polypeptide.

70. (new) The method of claim 69 wherein the heterologous polypeptide is an immunoglobulin constant domain.

71. (new) The method of claim 67 wherein the inflammatory disease or disorder is inflammatory bowel disease.

72. (new) The method of claim 67 wherein the inflammatory disease

or disorder is psoriasis.

73. (new) A method of treating or preventing inflammation comprising administering to an animal a therapeutically effective amount of a polypeptide selected from the group consisting of: (a) a polypeptide comprising amino acid residues 1 to 300 of SEQ ID NO:1; (b) a polypeptide comprising amino acid residues 24 to 300 of SEQ ID NO:1; (c) a polypeptide comprising amino acid residues 24 to 215 of SEQ ID NO:1; (d) a polypeptide comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254; and (f) a polypeptide comprising the amino acid sequence of the mature form of the polypeptide encoded by the CDNA contained in ATCC Deposit Number 209254.

74. (new) The method of claim 73 wherein the animal is human.

75. (new) The method of claim 73 wherein the polypeptide is fused to a heterologous polypeptide.

76. (new) The method of claim 75 wherein the heterologous polypeptide is an immunoglobulin constant domain.

77. (new) A method of treating or preventing an autoimmune disease or disorder comprising administering to an animal a therapeutically effective amount of a polypeptide selected from the group consisting of: (a) a polypeptide comprising amino acid residues 1 to 300 of SEQ ID NO:1; (b) a polypeptide comprising amino acid residues 24 to 300 of SEQ ID NO:1; (c) a polypeptide comprising amino acid residues 24 to 215 of SEQ ID NO:1; (d) a polypeptide comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254; and (e) a polypeptide comprising the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254.

78. (new) The method of claim 77 wherein the animal is human.

79. (new) The method of claim 77 wherein the polypeptide is fused to a heterologous polypeptide.

80. (new) The method of claim 79 wherein the heterologous polypeptide is an immunoglobulin constant domain.

81. (new) The method of claim 77 wherein the autoimmune disease or disorder is systemic lupus erythematosus.

82. (new) The method of claim 77 wherein the autoimmune disease or disorder is arthritis.

83. (new) The method of claim 77 wherein the autoimmune disease or disorder is rheumatoid arthritis.

84. (new) The method of claim 77 wherein the autoimmune disease or disorder is multiple sclerosis.

85. (new) The method of claim 77 wherein the autoimmune disease or disorder is Crohn's disease.

86. (new) A method of treating or preventing graft vs. host disease (GVHD) comprising administering to an animal a therapeutically effective amount of a polypeptide selected from the group consisting of: (a) a polypeptide comprising amino acid residues 1 to 300 of SEQ ID NO:1; (b) a polypeptide comprising amino acid residues 24 to 300 of SEQ ID NO:1; (c) a polypeptide comprising amino acid residues 24 to 215 of SEQ ID NO:1; (d) a polypeptide comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254; and (e) a polypeptide comprising the amino acid sequence of the mature form of the polypeptide encoded by the cDNA

contained in ATCC Deposit Number 209254.

87. (new) The method of claim 86 wherein the animal is human.

88. (new) The method of claim 86 wherein the polypeptide is fused to a heterologous polypeptide.

89. (new) The method of claim 88 wherein the heterologous polypeptide is an immunoglobulin constant domain.

90. (new) A method of treating or preventing allergy or asthma comprising administering to an animal a therapeutically effective amount of a polypeptide selected from the group consisting of: (a) a polypeptide comprising amino acid residues 1 to 300 of SEQ ID NO:1; (b) a polypeptide comprising amino acid residues 24 to 300 of SEQ ID NO:1; (c) a polypeptide comprising amino acid residues 24 to 215 of SEQ ID NO:1; (d) a polypeptide comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254; and (e) a polypeptide comprising the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254.

91. (new) The method of claim 90 wherein the animal is human.

92. (new) The method of claim 90 wherein the polypeptide is fused to a heterologous polypeptide.

93. (new) The method of claim 92 wherein the heterologous polypeptide is an immunoglobulin constant domain.